Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

30 Jun 2022

Red Light Holland Signs Deal with Wiz Khalifa to Launch Mushroom Brand

Red Light Holland has added another big name to their creative form of psychedelic entrepreneurism by signing a deal with hip hop superstar Wiz Khalifa....

By Microdose NewsDesk

Don’t Miss

28 Jun 2022

News You Might Have Missed: June 28th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

27 Jun 2022

Cybin Receives FDA Clearance for Phase 1/2a Trial

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder...

By Microdose NewsDesk

Industry

24 Jun 2022

Wonder Sciences Launches Wondermed At-Home Ketamine Treatments

There's a new player on the at-home scene, with Wondermed launching its own at-home ketamine service....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

23 Jun 2022

Ceruvia Lifesciences Submits Phase 1 Trial Application With the FDA

Based on a positive pre-IND meeting with the U....

By Microdose NewsDesk

Finance

21 Jun 2022

KPMG Releases Positive Report on Psychedelics

The news of KPMG putting out a report on psychedelics was low-key big news, and can go a long way in legitimizing the space in the eyes of more conservative...

By Microdose NewsDesk

Industry

20 Jun 2022

FDA Clears Mydecine’s MYCO-001 for Government Funded Trial

The trial is funded by a near $4 million grant from the National Institutes of Health, making this the first time in 50 years the U....

By Microdose NewsDesk

Don’t Miss

20 Jun 2022

News You Might Have Missed: June 20th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Don’t Miss

13 Jun 2022

News You Might Have Missed: June 13th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.